Brief: Adagio Medical Holdings, Receives FDA Breakthrough Device Designation For The Vclastm Cryoablation System
17/04/2025 13:52
April 17 (Reuters) - Adagio Medical Holdings Inc ADGM.O: ADAGIO MEDICAL HOLDINGS, INC. RECEIVES FDA BREAKTHROUGH DEVICE DESIGNATION FOR THE VCLASTM CRYOABLATION SYSTEM Source text: ID:nBw5XftzMa Further company coverage: ADGM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adagio Medical Holdings
See all newsBrief: Adagio Medical Submits Premarket Approval Application To FDA For Vclas® Ventricular Ablation System
Brief: Adagio Medical Announces Positive Pivotal Results For vCLAS Ventricular Ablation System
U.S. RESEARCH ROUNDUP-Biogen, Equinix, Revolution Medicines
U.S. STOCKS ON THE MOVE-Meta, Legence, Chegg
Adagio Medical rises after FDA clears expanded testing of heart device